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Abstract. 
 
We have reconstituted the platelet glycopro-
tein (GP) Ib-IX–mediated activation of the integrin 
 
a
 
IIb
 
b
 
3
 
 in a recombinant DNA expression model, and 
show that 14-3-3 is important in GPIb-IX signaling. 
CHO cells expressing 
 
a
 
IIb
 
b
 
3
 
 adhere poorly to vWF. 
Cells expressing GPIb-IX adhere to vWF in the pres-
ence of botrocetin but spread poorly. Cells coexpress-
ing integrin 
 
a
 
IIb
 
b
 
3
 
 and GPIb-IX adhere and spread on 
vWF, which is inhibited by RGDS peptides and anti-
bodies against 
 
a
 
IIb
 
b
 
3
 
. vWF binding to GPIb-IX also ac-
tivates soluble ﬁbrinogen binding to 
 
a
 
IIb
 
b
 
3
 
 indicating 
that GPIb-IX mediates a cellular signal leading to 
 
a
 
IIb
 
b
 
3
 
 activation. Deletion of the 14-3-3–binding site in 
GPIb
 
a
 
 inhibited GPIb-IX–mediated ﬁbrinogen binding 
to 
 
a
 
IIb
 
b
 
3
 
 and cell spreading on vWF. Thus, 14-3-3 bind-
ing to GPIb-IX is important in GPIb-IX signaling. Ex-
pression of a dominant negative 14-3-3 mutant inhib-
ited cell spreading on vWF, suggesting an important 
role for 14-3-3. Deleting both the 14-3-3 and ﬁlamin-
binding sites of GPIb
 
a
 
 induced an endogenous inte-
grin-dependent cell spreading on vWF without requir-
ing 
 
a
 
IIb
 
b
 
3
 
, but inhibited vWF-induced ﬁbrinogen
binding to 
 
a
 
IIb
 
b
 
3
 
. Thus, while different activation mech-
anisms may be responsible for vWF interaction with 
different integrins, GPIb-IX–mediated activation of 
 
a
 
IIb
 
b
 
3
 
 requires 14-3-3 interaction with GPIb
 
a
 
.
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P
 
LATELET
 
 adhesion to the subendothelial matrix plays
a critical role in thrombosis and hemostasis. Initial
platelet adhesion is mediated by the interaction
between a platelet receptor for von Willebrand factor
(vWF), the glycoprotein Ib-IX complex (GPIb-IX), and
matrix-bound vWF (Sakariassen et al., 1979, 1986; Savage
et al., 1996, 1998). This interaction is particularly impor-
tant under high shear flow conditions. Subsequently,
platelets firmly adhere and spread on vWF, and aggregate
to form a primary thrombus (Weiss et al., 1986; Savage et al.,
1996, 1998). Platelet spreading is dependent upon activa-
tion of integrin 
 
a
 
IIb
 
b
 
3
 
 interaction with the RGD sequence
in vWF, and platelet aggregation is dependent upon acti-
vation of integrin 
 
a
 
IIb
 
b
 
3
 
 binding to soluble fibrinogen (for
reviews see Phillips et al., 1991; Ruggeri and Ware, 1993;
Du and Ginsberg, 1997). Thus far, the GPIb-IX–mediated
signaling pathway leading to integrin activation has been
unclear.
GPIb-IX consists of three subunits: GPIb
 
a
 
, GPIb
 
b
 
, and
GPIX. GPIb-IX is loosely associated with glycoprotein V.
The NH
 
2
 
-terminal domain of GPIb
 
a
 
 contains binding sites
for vWF and thrombin (for reviews see Lopez, 1994; Ware,
1998). In vivo, binding of vWF to GPIb-IX does not occur
unless vWF first interacts with exposed subendothelial
matrix components such as collagen VI (Mazzucato et al.,
1999). Collagen probably induces a conformational change
in vWF exposing the binding site for GPIb
 
a
 
 (Mazzucato
et al., 1999). In vitro, the effect of collagen on vWF is mim-
icked by desialation of vWF or by vWF modulators such as
ristocetin or botrocetin which similarly induce vWF bind-
ing to the same binding pocket in the NH
 
2
 
-terminal region
of GPIb
 
a
 
 (Berndt et al., 1988; Vicente et al., 1988; An-
drews et al., 1989). The cytoplasmic domain of GPIb
 
a
 
 con-
tains a binding site for filamin (also called actin-binding
protein or ABP-280), which links GPIb-IX to cross-linked
actin filamental structures underlining the plasma mem-
brane (the membrane skeleton; Fox, 1985a,b). We found
that an intracellular signaling molecule, 14-3-3
 
z
 
, is also as-
sociated with GPIb-IX (Du et al., 1994), and a binding site
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for 14-3-3
 
z
 
 is located in a 15–amino acid residue region
(residues 595–610) at the COOH terminus of GPIb
 
a
 
 (Du
et al., 1996), distinct from the binding site for filamin (resi-
dues 536–568; Andrews and Fox, 1992). Binding of 14-3-3
to GPIb
 
a
 
 is regulated by phosphorylation of GPIb
 
a
 
 at
serine
 
609
 
 (Bodnar et al., 1999). 14-3-3 binding also involves
an additional 14-3-3–binding site in GPIb
 
b
 
 regulated by
protein kinase A (PKA; Andrews et al., 1998; Calverley et
al., 1998). The 14-3-3 family of highly conserved intracellu-
lar proteins interacts with serine phosphorylated intracel-
lular proteins (Furukawa et al., 1993; Fanti et al., 1994;
Freed et al., 1994; Fu et al., 1994; Pallas et al., 1994; Acs
et al., 1995; Bonnefoy et al., 1995; Conklin et al., 1995; Liu
et al., 1996; Meller et al., 1996), and regulates their func-
tions (Fanti et al., 1994; Ford et al., 1994; Li et al., 1995;
Zha et al., 1996; Tzivion et al., 1998). A recognition motif,
RSXpSXP, has been identified in several 14-3-3 ligands
(Muslin et al., 1996; Yaffe et al., 1997). Interaction with
RSXpSXP-motif–containing proteins requires helix G of
14-3-3
 
z
 
 (Gu and Du, 1998). In contrast, GPIb
 
a
 
 binding re-
quires the helix I region of 14-3-3
 
z
 
 distinct from the site re-
quired for binding of RSXpSXP-containing ligands (Gu
and Du, 1998).
In this study, we have established a CHO cell expression
model for studying GPIb-IX–mediated integrin activation.
We show that deletion of the 14-3-3–binding site in the
COOH terminus of GPIb
 
a
 
 inhibits GPIb-IX–induced in-
tegrin activation. Further, we show that expression of a
dominant negative mutant of 14-3-3 containing the GPIb-
IX–binding site also inhibits vWF induced integrin activa-
tion. Thus, 14-3-3 plays important roles in vWF-induced
GPIb-IX signaling leading to 
 
a
 
IIb
 
b
 
3
 
 activation. In addi-
tion, deleting both the filamin and 14-3-3–binding sites in
GPIb
 
a
 
 enhanced cell spreading on vWF. This did not re-
quire 
 
a
 
IIb
 
b
 
3
 
, but did require an endogenous integrin. The
same deletion mutant, however, failed to mediate vWF-
induced fibrinogen binding, suggesting that 
 
a
 
IIb
 
b
 
3
 
 activa-
tion was inhibited. Thus, different mechanisms may be re-
sponsible for vWF interaction with different integrins after
GPIb-IX–mediated initial adhesion.
 
Materials and Methods
 
Reagents
 
An anti-peptide antibody, anti-Ib
 
a
 
C, recognizing the COOH-terminal do-
main of GPIb
 
a
 
 has been described previously (Du et al., 1996). The mono-
clonal antibodies WM23 and AK2 against GPIb
 
a
 
,
 
 and purification of
vWF and botrocetin were as described previously (Berndt et al., 1985; An-
drews et al., 1989). The monoclonal antibody against GPIb
 
a
 
, P3221, was
kindly provided by Dr. Zaverio Ruggeri (The Scripps Research Institute,
La Jolla, CA). mAbs D57 and 15 against integrin 
 
a
 
IIb
 
b
 
3
 
 were kindly pro-
vided by Dr. Mark Ginsberg (The Scripps Research Institute, La Jolla,
CA). Monoclonal antibody, 4F10, against integrin 
 
a
 
IIb
 
b
 
3
 
 complex was
kindly provided by Dr. Virgil Woods (University of California at San Di-
ego, CA). Monoclonal antibody against GPIb
 
a
 
,
 
 SZ2, monoclonal anti-
body against human 
 
b
 
3
 
, SZ21, and monoclonal antibody against vWF,
SZ29, were generous gifts from Dr. Changgeng Ruan (Suzhou Medical
College, Suzhou, China; Ruan et al., 1987a,b); cDNA clones encoding 
 
a
 
IIb
 
and 
 
b
 
3
 
 in CDM8 vector were kindly provided by Dr. Mark Ginsberg. In
some experiments, botrocetin was also purchased from Centerchem. Ris-
tocetin was purchased from Sigma Chemical Co.
DNA encoding wild-type and mutant 14-3-3
 
z
 
 was described previously
(Du et al., 1996; Gu and Du, 1998). The wild-type and mutant 14-3-3
 
z
 
were subcloned into pEGFP-C2 vector (Clonetech) between EcoRI and
XbaI sites. The constructs encode a wild-type or a mutant 14-3-3
 
z
 
 fused to
the COOH terminus of green fluorescent protein (GFP)
 
1
 
.
 
Cell Lines Expressing Recombinant Proteins
 
Transfections of cDNA into CHO cells were performed according to the
previously described methods using Lipofectamine (BRL; Du et al., 1996).
Selection markers (CDneo and CDhygro; Invitrogen) were cotransfected
with desired DNA at a 1:10 ratio. Stably transfected cell lines were se-
lected in selection media containing 0.5 mg/ml G418 and/or 0.2 mg/ml hy-
gromycin, and further selected by mass cell sorting using antibodies recog-
nizing GPIb
 
a
 
 (P3221) and/or integrin 
 
a
 
IIb
 
b
 
3
 
 (D57). The following cell
lines were established: cells expressing GPIb-IX complex (1b9) (Du et al.,
1996); cells expressing integrin 
 
a
 
IIb
 
b
 
3
 
 (2b3a); cells coexpressing GPIb-IX
and 
 
a
 
IIb
 
b
 
3
 
 (123); and cells coexpressing integrin 
 
a
 
IIb
 
b
 
3
 
 and GPIb-IX mu-
tants with truncated GPIb
 
a
 
 cytoplasmic domains at residues 591 (
 
D
 
591/
2b3a) and 559 (
 
D
 
559/2b3a) (Du et al., 1996). Cells expressing comparable
levels of integrins or/and GPIb-IX were further selected by cell sorting
and monitored by flow cytometry.
 
Cell Adhesion Assay
 
Microtiter wells were coated with 10 
 
m
 
g/ml vWF or fibrinogen in PBS at
4
 
8
 
C overnight. Cells in Tyrode’s buffer in the presence of 5 
 
m
 
g/ml botroce-
tin were incubated in ligand-coated microtiter wells for 30 min at 37
 
8
 
C in a
CO
 
2
 
 incubator. As adhesion of the GPIb-IX and integrin-transfected
CHO cells to vWF does not require botrocetin, botrocetin was omitted in
some experiments. After three washes, cell spreading was examined under
an inverted microscope (20
 
3
 
 objective lens). In quantitative assays, 50 
 
m
 
l
of 0.3% 
 
p
 
-nitrophenyl phosphate in 1% Triton X-100, 50 mM sodium ace-
tate, pH 5.0, was added to microtiter wells and incubated at 37
 
8
 
C for 1 h.
The reaction was stopped by adding 50 
 
m
 
l of 1 M NaOH. Results were de-
termined by reading OD at 405 nm wave length. A standard curve of acid
phosphatase reaction was established by adding the acid phosphatase sub-
strate to various known numbers of the same cells in parallel wells. Acid
phosphatase assay of the standards confirmed that the OD value was pro-
portional to cell number. The rate of cell adhesion was estimated from the
ratio of the numbers of adherent cells to that of total cells.
 
Fluorescence Microscopy
 
Cells were allowed to adhere and spread on vWF- or fibrinogen-coated
glass chamber slides (Nunc). After three washes, cells were fixed by add-
ing 4% paraformaldehyde in PBS. In experiments that required cell per-
meabilization, cells were permeabilized by adding 0.1 M Tris, 0.01 M
EGTA, 0.15 M NaCl, 5 mM MgCl
 
2
 
, pH 7.4, containing 0.1% Triton X-100,
0.5 mM leupeptin, 1 mM PMSF, and 0.1 mM E64. The cells were then in-
cubated with 20 
 
m
 
g/ml of various antibodies at 22
 
8
 
C for 1 h. After three
washes, cells were further incubated with fluorescein- or rhodamine-
labeled secondary antibodies at 22
 
8
 
C for 30 min. To stain the actin fila-
ments, rhodamine-labeled phalloidin (Sigma Chemical Co.) was also
added. After additional washes, cells were photographed under a fluores-
cence microscope. In some experiments, the data were collected by a
cooled CCD camera and surface area quantitated using Image-Pro Plus
(Media Cybernetics).
 
Flow Cytometry Analysis of vWF Binding and
vWF-induced Fibrinogen Binding
 
Fluorescein-labeling of fibrinogen was prepared as described previously
(Chen et al., 1994). Cells expressing recombinant proteins were harvested
and suspended in modified Tyrode’s buffer (Du et al., 1991). Cells (
 
z
 
1
 
 3
 
10
 
7
 
/ml) were incubated for 30 min with 15 
 
m
 
g/ml fluorescein-labeled fi-
brinogen in the presence of 20 
 
m
 
g/ml vWF and 1 mg/ml ristocetin. As a
negative control, cells were also incubated with fluorescein-labeled fibrin-
ogen in the presence of 1 mg/ml ristocectin but in the absence of vWF.
RGDS peptide (1 mM) was added in parallel assays for estimation of spe-
cific fibrinogen binding to the integrin. We showed previously that 1 mM
RGDS completely abolished fibrinogen binding to integrin 
 
a
 
IIb
 
b
 
3
 
 while 1
mM RGES had no effect (Du et al., 1991). Fibrinogen binding was ana-
lyzed by flow cytometry.
 
1. 
 
Abbreviations used in this paper:
 
 GFP, green fluorescent protein; GP,
glycoprotein; PGE
 
1
 
, prostaglandin E
 
1
 
; PKA, protein kinase A; vWF, von
Willebrand factor. 
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For vWF binding, the cells in Tyrode’s buffer were incubated for 30
min at 22
 
8
 
C with vWF in the presence 1 mg/ml ristocetin. After washing,
the cells were further incubated for 30 min with a monoclonal antibody
against vWF, SZ29, and then analyzed by flow cytometry.
 
Immunoprecipitation
 
CHO cells coexpressing integrin 
 
a
 
IIb
 
b
 
3
 
 with wild-type GPIb-IX (123 cells)
or GPIb-IX mutant 
 
D
 
591 were solubilized as previously described (Gu
and Du, 1998). Cell lysates were incubated with 10 mg of WM23 against
GPIba or mouse IgG (Sigma Chemical Co.) at 48C for 1 h and further in-
cubated for 1 h after addition of protein G–conjugated Sepharose beads
(Sigma Chemical Co.). After three washes, the bead-bound proteins were
analyzed by SDS-PAGE and Western blotting with a rabbit anti-GPIba
antibody or a rabbit antibody against 14-3-3z (Du et al., 1996). Reaction of
the antibodies was visualized using an enhanced chemiluminescence kit
(Amersham-Pharmacia).
Results
Roles of GPIb-IX and aIIbb3 in Mediating Cell Adhesion 
to vWF
To analyze the roles of GPIb-IX and integrin aIIbb3 in
vWF-mediated platelet adhesion and activation, stable
CHO cell lines were established that express one of the
two platelet receptors for vWF: GPIb-IX (1b9 cells) or in-
tegrin aIIbb3 (2b3a cells). A stable cell line was also estab-
lished that expressed both GPIb-IX and integrin aIIbb3 at
levels comparable to 1b9 and 2b3a cells, respectively (123
cells; Fig. 1 A). These cells were incubated in vWF-coated
microtiter wells for 30 min in the presence of botrocetin,
which binds to vWF and mimics the effects of subendothe-
lial matrix to induce vWF binding to GPIb-IX (Andrews
et al., 1989). As a positive control, these cells were also in-
cubated in fibrinogen-coated microtiter wells. Adherent
cells were quantitated with an acid-phosphatase assay. As
shown in Fig. 1, ,10% of the 2b3a cells (expressing only
aIIbb3) adhered to the vWF-coated surface compared with
z55% adhesion to fibrinogen, suggesting only a back-
ground level of vWF-integrin interaction. This result is
consistent with previous work showing a low affinity state
of aIIbb3 expressed in CHO cells (O’Toole et al., 1990),
and is also consistent with results obtained in platelets
showing that integrin aIIbb3 interacts poorly with vWF
without prior activation (Savage et al., 1992). The possibil-
ity of defective integrin function and expression in 2b3a
cells can be excluded, as both the 2b3a cells and 123 cells
but not 1b9 cells adhered to immobilized fibrinogen which
is known to interact with integrin aIIbb3 without prior acti-
vation (Coller, 1980; Savage et al., 1995; Fig. 1 B). Thus,
vWF is a poor ligand for unactivated integrin aIIbb3.
In contrast to cells expressing aIIbb3 (2b3a cells), those
expressing GPIb-IX (1b9 cells) or those expressing both
GPIb-IX and integrin aIIbb3 (123 cells), adhered to vWF-
coated wells in the presence of botrocetin (Fig. 1 B). As
platelet adhesion to immobilized vWF occurs in the ab-
sence of vWF modulators (Savage et al., 1992), we further
examined the adhesion of 123 cells to immobilized vWF
without botrocetin treatment. Fig. 1 C shows that 123 cell
adhesion to vWF does not require botrocetin, indicating
that adhesion of CHO cells expressing GPIb-IX and aIIbb3
to vWF is similar to platelet adhesion. Furthermore, ad-
hesion of 123 cells to vWF was inhibited by monoclonal
antibodies against vWF-binding site of GPIba (Fig. 1 C).
Figure 1. Adhesion of cells expressing recombinant receptors for
vWF. (A) Cells expressing integrin aIIbb3 (2b3a), cells expressing
GPIb-IX (1b9) and cells expressing both GPIb-IX and aIIbb3
(123) are described in Materials and Methods. These cells were
detached and incubated with biotin-labeled monoclonal antibody
WM23 (against GPIba) at 228C for 30 min, and then incubated
with phycoerythrin-labeled streptavidin and FITC-labeled mono-
clonal antibody D57 (against integrin aIIbb3) at 228C for 30 min.
The cells were then analyzed by flow cytometry. (B) The cells de-
scribed in A were incubated in vWF-coated microtiter wells for
30 min at 378C in the presence of 5 mg/ml botrocetin. Untrans-
fected CHO cells were also used as a negative control. To com-
pare the function of aIIbb3 expressed in 123 and 2b3a cells, cells
are also incubated with fibrinogen (Fg)-coated wells. After wash-
ing, the adherent cells were quantitated by an acid phosphatase
assay as described in Materials and Methods. Shown in the figure
are the results from triplicate samples (mean 6 SD). (C) 123
cells, 2b3a and CHO cells were also allowed to adhere to (10 mg/
ml) vWF-coated microtiter wells in the absence of botrocetin. 123
cells were also preincubated with control IgG, or the monoclonal
antibodies, AK2 and SZ2 against the vWF-binding site of GPIba,
and then allowed to adhere to vWF-coated wells in the absence
of botrocetin. Note that AK2 and SZ2 inhibited cell adhesion
to vWF.The Journal of Cell Biology, Volume 147, 1999 1088
These results suggest that, as in platelets, GPIb-IX is re-
quired for cell adhesion to vWF in this CHO cell expres-
sion model.
GPIb-IX Induces Integrin-vWF Interaction and 
Integrin-dependent Cell Spreading on vWF
Under a microscope, most adherent 1b9 cells (expressing
GPIb-IX only) on vWF showed a rounded morphology
similar to nonadherent cells (Fig. 2 A). In contrast, 123
cells (coexpressing GPIb-IX and aIIbb3) spread on the
vWF-coated surface (Fig. 2 A). Spreading of 123 cells was
abolished by RGDS peptide (Fig. 2 A), indicating that
spreading was mediated by integrins. Spreading of 123
cells was also inhibited by the monoclonal antibody 4F10,
against human aIIbb3 complex, and by anti-human b3 anti-
body SZ21 (Fig. 2 A). These data indicated that spreading
was mainly mediated by integrin aIIbb3 and that endoge-
nous integrins were unlikely to play a major role. It is un-
likely that coexpression of GPIb-IX with aIIbb3 in the 123
cell line resulted in constitutively active integrin aIIbb3, as
123 cells did not bind to soluble fibrinogen without prior
activation (data not shown, see Fig. 3). Thus, vWF binding
to GPIb-IX induces integrin-vWF interaction and inte-
Figure 2. GPIb-IX activates
integrin-vWF interaction
and  integrin-dependent cell
spreading on vWF. (A) Three
CHO cell lines, 1b9 (ex-
pressing GPIb-IX), 2b3a
(expressing  aIIbb3), and 123
(expressing GPIb-IX and in-
tegrin aIIbb3) were incubated
in the microtiter plates coated
with 10 mg/ml vWF for 30 min
at 378C in the presence of 5
mg/ml botrocetin. 123 cells
were also incubated in the
vWF-coated wells in the pres-
ence of 2 mM of the integrin
antagonist peptide, RGDS
(1231RGDS), a monoclonal
antibody specific for integrin
aIIbb3 complex (12314F10)
and a monoclonal anti-
body  against human b3
(1231SZ21) at 100 mg/ml,
500 ng/ml prostaglandin E1
(PGE1), 25 nM calphostin C,
and 0.1 mM Wortmannin. (B)
To compare aIIbb3 function,
2b3a cells and 123 cells were
incubated in microtiter wells
coated with 10 mg/ml fibrino-
gen. After washing, the ad-
herent cells were photo-
graphed under a phase
contrast microscope (203 ob-
jective lens). (C) Cells ex-
pressing GPIb-IX (1b9) and
coexpressing both aIIbb3 and
GPIb-IX (123) were allowed
to adhere to botrocetin-
treated vWF-coated glass
slides in the absence or pres-
ence of RGDS peptide. Af-
ter fixation and permeabiliza-
tion, cells were stained with
rhodamine-labeled phalloi-
din, and photographed under
a fluorescence microscope
(403 objective lens).Gu et al. Integrin Activation by GPIb-IX 1089
grin-mediated cell spreading. To examine whether GPIb-
IX–mediated signaling pathway in CHO cells mimics that
in platelets, we examined the effects of platelet activation
inhibitors. We found that the PGE1, which elevates intra-
cellular cAMP, wortmannin, and calphostin C, which in-
hibit PI-3 kinase and PKC, respectively, also inhibited
GPIb-IX and integrin-dependent CHO cell spreading on
vWF. Thus, GPIb-IX expressed in CHO cells induced in-
tegrin interaction with vWF in a manner similar to that in
platelets.
To further exclude the possibility that integrin function
in 123 cells may differ from that in the 2b3a cell line, we
also examined integrin-mediated cell spreading on immo-
bilized fibrinogen. Both 2b3a cells and 123 cells fully
spread on immobilized fibrinogen (Fig. 2 B), suggesting
that aIIbb3 expressed in both cell lines functioned in a simi-
lar manner. As shown above, only a small percentage of
2b3a cells adhere to vWF. Some of these adherent cells,
however, also spread on vWF, suggesting that the back-
ground level GPIb-IX–independent interaction of aIIbb3
with vWF in a small percentage of 2b3a cells can also me-
diate cell spreading.
To examine the morphological changes in more detail,
the adherent cells were stained with fluorescently labeled
phalloidin, and examined by fluorescence microscopy un-
der high magnification. Only 5% of 1b9 cells spread on
vWF (Fig. 2 C). Most 1b9 cells did not spread or only
poorly spread on vWF. However, 58% of these poorly
spread cells showed limited filopodium- or lamellipodium-
like structures extending to the vWF-coated surface (Fig. 2
C) which was inhibited by RGDS peptide. This indicates a
low level interaction between vWF and an endogenous in-
tegrin, which is consistent with the results obtained by
Cunningham et al. (1996). In contrast to 1b9 cells, z70%
of 123 cells (expressing both GPIb-IX and integrin aIIbb3)
fully spread, which was inhibited by RGDS peptide (Fig. 2
C). These results show that GPIb-IX induces integrin
aIIbb3 interaction with vWF which is responsible for 123
cell spreading on vWF.
vWF-induced Fibrinogen Binding to Integrin aIIbb3 in 
CHO Cells
Two possible mechanisms could explain GPIb-IX–induced
integrin-vWF interaction in the CHO cell expression
model: (a) GPIb-IX may induce a cellular signal that in-
creases the affinity of integrin for vWF (activation); or (b)
the GPIb-IX binding to vWF may allow access of integrin
to vWF, e.g., by changing the conformation of vWF. To
differentiate between these two possibilities, we examined
whether vWF activated integrin binding to another ligand
of aIIbb3, soluble fibrinogen, in 123 cells. It is known that
integrin aIIbb3 binds soluble fibrinogen only after the inte-
grin is activated (for reviews, see Du and Ginsberg, 1997;
Phillips et al., 1991). FITC-labeled fibrinogen was incu-
bated with 123 cells in the presence of ristocetin which is
known to induce soluble vWF binding to GPIb-IX and
vWF-dependent platelet aggregation but not to induce fi-
brinogen-dependent platelet aggregation in the absence of
vWF (for review, see Ware, 1998). As expected, there was
no specific fibrinogen binding to 123 cells exposed only to
ristocetin, indicating that ristocetin alone does not induce
specific fibrinogen binding to integrin aIIbb3 (Fig. 3 A).
When both vWF and ristocetin were present, however,
there was significant binding of fibrinogen. vWF-induced
fibrinogen binding was inhibited by RGDS peptide (Fig. 3,
B and E), and was also inhibited by an anti-GPIba mono-
Figure 3. GPIb-IX–induced soluble fibrinogen binding to inte-
grin aIIbb3. (A) Cells expressing both GPIb-IX and integrin aIIbb3
(123 cells) were incubated with FITC-labeled fibrinogen (15 mg/ml)
and 1 mg/ml ristocetin in the absence (Fg) or presence of RGDS
peptide (Fg1RGDS). (B) 123 cells were incubated with FITC-
labeled fibrinogen, ristocetin, and 20 mg/ml purified human vWF
in the absence of RGDS (Fg) or in the presence of RGDS
(Fg1RGDS). (C) Control mouse IgG or a monoclonal antibody
against GPIba, AK2, were added to 123 cells. The cells were then
incubated with FITC-labeled fibrinogen, ristocetin and vWF.
Note that the increased binding of fibrinogen in the presence of
vWF was inhibited by RGDS and by AK2. (D) 2b3a cells ex-
pressing aIIbb3 only were incubated with FITC-labeled fibrino-
gen, vWF and ristocetin. Cells in A–D were analyzed for fibrino-
gen binding by flow cytometry. (E) 123 cells were incubated with
FITC-labeled fibrinogen in the presence of ristocetin only (Con-
trol), ristocetin and RGDS (1RGDS), ristocetin and vWF
(1vWF), or ristocetin, vWF and RGDS (1vWF1RGDS) at
228C for 30 min and examined for fibrinogen binding as de-
scribed in A. Activation of fibrinogen binding was quantitated
and expressed as an activation index which is the ratio of the flu-
orescence intensity (Geo mean) of sample cells over the fluores-
cence intensity (Geo mean) of the control 123 cells (not stimu-
lated with vWF). Shown in E are the results of 4 experiments
(mean 6 SD). Student’s t test revealed that the difference be-
tween control and vWF-stimulated (1vWF) fibrinogen binding is
highly significant (P , 0.001).The Journal of Cell Biology, Volume 147, 1999 1090
clonal antibody, AK2, known to inhibit ristocetin-induced
vWF binding to GPIb-IX (Fig. 3 C). Furthermore, vWF
did not induce specific fibrinogen binding to 2b3a cells
(Fig. 3 D), suggesting that vWF-induced fibrinogen bind-
ing to integrin aIIbb3 requires vWF interaction with GPIb-
IX. Thus, vWF interaction with GPIb-IX not only stimu-
lates vWF-aIIbb3 interaction, but also induces the integrin
to bind soluble fibrinogen. These data indicate that risto-
cetin-dependent vWF binding to GPIb-IX induces a cellu-
lar signal that activates the ligand-binding function of
aIIbb3.
Effects of GPIba Cytoplasmic Domain Deletion 
Mutagenesis on 14-3-3–binding Function of GPIb-IX
We showed previously (Du et al., 1996) that the intracellu-
lar signaling molecule 14-3-3z binds to a site in the
COOH-terminal 15 residues (residues 595–610) of the cy-
toplasmic domain of GPIba. To investigate the role of 14-
3-3 in GPIb-IX–mediated activation of aIIbb3 in the CHO
cell model, we established a CHO cell line (D591/2b3a
cells) that coexpresses aIIbb3 and a mutant GPIb-IX, D591,
that lacks the 14-3-3–binding site (18 residues) at the
COOH terminus of GPIba, but retains the functional fil-
amin-binding domain in GPIba (Cunningham et al., 1996;
Du et al., 1996). As shown in Fig. 4, wild-type GPIb-IX ex-
pressed in CHO cells (123 cells) coimmunoprecipitates
with an endogenous CHO cell 14-3-3 protein reactive with
anti–14-3-3z antibodies (Fig. 4). The mutant GPIb-IX
(D591), however, failed to coimmunoprecipitate endoge-
nous CHO cell 14-3-3 (Fig. 4). As a control, we also im-
munoblotted the same immunoprecipitates with an anti-
GPIba antibody, and observed that similar amounts of
GPIba were immunoprecipitated from both the D591/
2b3a cells and 123 cells (expressing wild-type GPIb-IX;
Fig. 4). Thus, the D591 mutant GPIb-IX is defective in
binding to endogenous 14-3-3.
Figure 4. Coimmunoprecipitation of endogenous CHO cell 14-3-3
with GPIb-IX. Cells were stably transfected with integrin aIIbb3
together with wild-type GPIb-IX (123) or GPIb-IX mutants with
GPIba cytoplasmic domain truncated at residue 591 to delete 14-
3-3–binding site (D591/2b3a). The 123 cells and D591/2b3a cells
were solubilized and immunoprecipitated with the monoclonal
antibody, WM23, against GPIba (Ib) or control mouse IgG (Ig).
Immunoprecipitates were analyzed by SDS-PAGE and immuno-
blotted with a rabbit antibody against 14-3-3z or a rabbit anti-
GPIba antibody. Note that 14-3-3z was coimmunoprecipitated
with wild-type GPIb-IX but not D591.
Figure 5. Deletion of the 14-3-3–bind-
ing site in the cytoplasmic domain of
GPIba inhibited GPIb-IX–induced in-
tegrin activation. Cells were trans-
fected with integrin aIIbb3 together
with wild-type GPIb-IX (123), a GPIb-
IX mutant lacking the 14-3-3–binding
site (D591/2b3a), or a GPIb-IX mutant
with deleted filamin and 14-3-3–bind-
ing sites (D559/2b3a). (A) The 123
cells, D591/2b3a and D559/2b3a cells
were incubated with FITC-labeled fi-
brinogen (20 mg/ml) at 228C for 30 min
in the presence of ristocetin only (1 mg/
ml; No vWF) or in the presence of 20
mg/ml vWF and ristocetin (1vWF). To
estimate nonspecific binding, these
cells were also incubated with FITC-
labeled fibrinogen in the presence of 1
mM RGDS peptide (1RGDS) known
to specifically inhibit fibrinogen bind-
ing to aIIbb3. The cells were then ana-
lyzed by flow cytometry. (B) 123 cells
or D591/2b3a cells were incubated with
biotin-labeled WM23 (against GPIba)
and FITC-labeled D57 (against aIIbb3).
As controls, CHO cells expressing
GPIb-IX only or aIIbb3 only were also
incubated with these antibodies at 228C
for 30 min. After washing and further
incubation with phycoerythrin-labeled
streptavidin, the cells were diluted in
Tyrode’s buffer and analyzed by flow
cytometry.Gu et al. Integrin Activation by GPIb-IX 1091
GPIb-IX–mediated Activation of the Integrin aIIbb3 
Requires the 14-3-3–binding Site in GPIba
To determine whether deletion of the 14-3-3–binding site
in GPIba affects GPIb-IX–mediated activation of the inte-
grin aIIbb3, we examined whether ristocetin-induced vWF
binding to the mutant GPIb-IX stimulates the binding of
FITC-labeled fibrinogen to D591/2b3a cells. Fig. 5 A
shows that vWF induces soluble fibrinogen binding to 123
cells which is inhibited by RGDS peptide. In contrast,
vWF-induced fibrinogen binding to D591/2b3a cells is ab-
sent. It is unlikely that the defect in fibrinogen binding to
D591/2b3a cells results from naturally occurring mutations
developed in the CHO cells during selection as the D591/
2b3a cells are established by mass sorting of cells reactive
with both antibodies against aIIbb3 and GPIb-IX and not
by single cell cloning. It is also unlikely that the inhibition
of integrin activation results from defective binding of
vWF as vWF binding to 591/2b3a cells is not negatively af-
fected (Fig. 6). As D591/2b3a cells adhered and spread on
fibrinogen (Fig. 7), the possibility of a defective integrin
function can be further excluded. Thus, our data indicate
that the 14-3-3–binding site of GPIba plays an important
role in GPIb-IX–mediated integrin activation.
We also examined vWF-induced fibrinogen binding to a
CHO cell line (D559/2b3a), expressing integrin aIIbb3 and
a truncation mutant GPIb-IX lacking both the 14-3-3–
binding domain and filamin-binding domain of GPIba. No
specific fibrinogen binding was detected in this cell line
suggesting that inhibition of aIIbb3 activation by deleting
the 14-3-3–binding site of GPIba was not reversed by fur-
ther deletion of the filamin-binding site of GPIba (Fig. 5).
The 14-3-3–binding Site of GPIb-IX Is Involved in 
GPIb-IX–induced Integrin-vWF Interaction and Cell 
Spreading on vWF
To investigate whether 14-3-3 binding plays a role in
GPIb-IX–induced integrin-vWF interaction and integrin-
dependent cell spreading on vWF, the 123 cells and D591/
2b3a cells were allowed to adhere to vWF-coated microti-
ter wells. As examined under the microscope, z70% of
the 123 cells were spread on both vWF- and fibrinogen-
coated microtiter wells. In contrast, only a small percent-
age (z30%) of D591/2b3a cells appeared spreading on
vWF, indicating that GPIb-IX–induced integrin-vWF in-
teraction was inhibited (Fig. 7). To quantitate the cell
spreading objectively, cells adherent to vWF were perme-
abilized and stained with rhodamine-labeled phalloidin.
Fluorescently stained cells in randomly selected fields
were quantitated for cell surface area using Image-Pro
Plus software (Media Cybernetics). As shown in Fig. 8, the
average surface area of D591/2b3a cells were about half of
that of 123 cells, indicating that the spreading of the mu-
tant cell line was significantly reduced but not totally abol-
ished. Since D591/2b3a cells adhered and spread on fibrin-
ogen in a manner similar to 123 cells, the ligand-binding
function of aIIbb3 and the integrin-mediated spreading
process was not impaired in the D591/2b3a cell line. Thus,
inhibition of GPIb-IX– and integrin-dependent spreading
on vWF in this cell line is unlikely to be caused by a defect
in ligand-binding function of aIIbb3 or in the integrin’s
post-ligand occupancy events. These data suggest that 14-
3-3z binding to the COOH-terminal region of GPIba plays
an important role in GPIb-IX–mediated activation of inte-
grin aIIbb3. Spreading of a small percentage of mutant cells
reflects a background level of aIIbb3-vWF interaction or
the interaction of vWF with the endogenous CHO cell in-
tegrin (see Fig. 2 C).
Effects of Disruption of GPIb-IX Interaction with 
Filamin on vWF Interaction with Integrins
It has been shown previously (Cunningham et al., 1996;
Du et al., 1996) that truncation of GPIb-IX at residue 559
Figure 6. Effects of truncation mutations on ristoce-
tin-induced vWF binding to GPIb-IX. The 2b3a cells
(expressing aIIbb3 only), 123 cells, D591/2b3a cells
and D559/2b3a cells were incubated with (1vWF) or
without (No vWF) vWF in the presence of 1 mg/ml
ristocetin. The cells were then stained with a mono-
clonal antibody, SZ29, specific for human vWF,
and analyzed by flow cytometry to estimate vWF
binding.The Journal of Cell Biology, Volume 147, 1999 1092
(D559) of GPIba abolishes filamin and 14-3-3 binding to
GPIb-IX, and induces GPIb-IX–dependent cell spreading
in the absence of integrin aIIbb3 (Cunningham et al., 1996).
To investigate functional effects of this truncation muta-
tion on GPIb-IX–dependent vWF interaction with differ-
ent integrins, we coexpressed D559 with integrin aIIbb3
(D559/2b3a). Not only did the D559/2b3a cells exhibit no
defect in spreading, but they actually showed enhanced
spreading on vWF compared with 123 cells (Figs. 7 and 8).
The spreading of D559/2b3a cells was significantly inhib-
ited by RGDS peptide but poorly inhibited by anti-aIIbb3
antibody 4F10 and anti-b3 antibody SZ21 (Fig. 7), suggest-
ing that an endogenous integrin plays a significant role.
This result is consistent with previous studies showing that
CHO cells expressing the same mutant of GPIb-IX spread
on vWF in the absence of integrin aIIbb3 (Cunningham et al.,
1996). However, when incubated with soluble fibrinogen
in the presence of vWF and ristocetin, no specific binding
of fibrinogen to D559/2b3a cells was detected (see Fig. 5).
These results indicate that deletion of both 14-3-3 and fil-
amin-binding sites of GPIba inhibited GPIb-IX–mediated
activation of fibrinogen binding to aIIbb3, but enhanced
the interaction of vWF with an endogenous integrin
(which only plays a very limited role in wild-type GPIb-
IX–mediated cell spreading (see Fig. 2 C). Thus, it appears
that two different mechanisms may be involved in the
vWF interaction with integrins: a GPIb-IX–mediated 14-
3-3-dependent mechanism that induces an activation sig-
nal leading to the activation of integrin aIIbb3, and an al-
ternative mechanism that allows the interaction of vWF
with an unidentified integrin. The latter mechanism be-
comes significant only when the association of GPIb-IX
with the membrane skeleton structure is disrupted.
Inhibition of GPIb-IX– and Integrin-dependent Cell 
Spreading by a 14-3-3 Fragment Containing the
GPIb-IX–binding Site
We have recently shown that GPIba binds to a site in the
helix I region of 14-3-3z, distinct from the sites required
for 14-3-3z binding to RSXpSXP-motif containing ligands
such as c-Raf (Gu and Du, 1998). To verify that 14-3-3z
plays a role in GPIb-IX signaling, we constructed cDNAs
encoding fusion proteins of green fluorescent protein
(GFP) with wild-type 14-3-3z (GFP-1433) as well as a
small fragment of 14-3-3z containing the GPIba-binding
site (1433T12, residues 188–231; Gu and Du, 1998). Tran-
sient expression of the wild-type and the mutant 14-3-3
Figure 7. Effects of trunca-
tion mutants of GPIba on
the GPIb-IX– and integrin-
dependent cell spreading on
vWF. Cell lines were estab-
lished that coexpressed inte-
grin  aIIbb3 together, either
with wild-type GPIb-IX
(123), or a GPIb-IX mutant
with the GPIba cytoplasmic
domain truncated at residue
591 to delete the 14-3-3–bind-
ing site (D591/2b3a), or at
residue 559 to delete both
14-3-3– and filamin-binding
sites (D559/2b3a). The cells
were incubated in microtiter
wells coated with 10 mg/ml
vWF or 10 mg/ml fibrinogen.
Adherent cells were photo-
graphed under phase contrast
microscope (203 objective
lens). D559/2b3a cells were
also  allowed to adhere to vWF
in the presence of RGDS pep-
tide (1 mM) or an antibody
against aIIbb3 complex, 4F10
(100 mg/ml), or an antibody
against  b3, SZ21.Gu et al. Integrin Activation by GPIb-IX 1093
was indicated by the emission of green fluorescence (Fig.
9). After transfection of pEGFP vector alone, z70% of
123 cells adhere and spread on vWF. Cells expressing
GFP-1433 fusion protein showed an increase in the per-
centage of spreading (85%), suggesting that overexpres-
sion of 14-3-3 enhanced cell spreading on vWF-coated
surface (Fig. 9). In contrast, 90% of the cells expressing
GFP-1433T12 fusion protein are rounded (Fig. 9), and the
rest (10% cells) only partially spread on vWF (not shown).
These results suggest that the small fragment of 14-3-3z in-
hibited the function of endogenous 14-3-3 in a dominant
negative fashion.
Discussion
In this study, we show that GPIb-IX binding to vWF in-
duces signals that activate the ligand-binding function of
integrin aIIbb3 and integrin-dependent cell spreading using
a reconstituted CHO cell expression model. We show that
vWF-induced GPIb-IX signaling is inhibited by deletion of
the 14-3-3–binding sites in the cytoplasmic domain of
GPIba (Figs. 5 and 7). Thus, our study indicates that inter-
action between GPIb-IX and 14-3-3 plays an important
role in GPIb-IX–mediated signaling leading to activation
of integrin aIIbb3.
Understanding the intracellular signaling mechanism in-
duced by ligand binding to the platelet vWF receptor,
GPIb-IX, as well as platelet signaling in general, has been
hampered by the lack of specific means to interfere with
platelet signaling intracellularly at a molecular level. Stud-
ies on the GPIb-IX–induced platelet activation by bio-
chemical approaches have shown that ligand binding to
GPIb-IX induces a series of intracellular biochemical
changes such as generation of thromboxane A2 (Kroll et al.,
1991), production of phosphatidic acid (Kroll et al., 1991),
activation of PI-3 kinase (Jackson et al., 1994), increase in
the cytoplasmic calcium level (Kroll et al., 1991; Ikeda et al.,
1993), and activation of protein kinases such as protein ki-
nase C (Kroll et al., 1991, 1993; Chow et al., 1992) and ty-
rosine kinases (Razdan et al., 1994; Asazuma et al., 1997).
The consequence of these intracellular signaling events is
the activation of integrin aIIbb3 (De Marco et al., 1985a,b;
Gralnick et al., 1985; Kroll et al., 1991; Savage et al., 1992,
1996). However, specific molecular pathways leading to
these signaling events are unclear. In many cell types, ad-
Figure 8. Quantitation of the effects of truncation mutations on
cell spreading. The 123, D591/2b3a, and D559/2b3a cells were in-
cubated for 1 h at 378C in vWF-coated chamber slides, washed,
fixed, and permeabilized. The cells were then stained with
rhodamine-labeled phalloidin, and photographed under a Nikon
fluorescence microscope using a cooled CCD camera. To esti-
mate the surface area of round cells, RGD-treated 123 cells were
allowed to adhere to vWF and stained with rhodamine-labeled
phalloidin as above. Three randomly selected fields (for each cell
line) were then analyzed for surface area of adherent cells using
Image-Pro Plus software. Results were expressed as mean 6 SD
(for 123 cells, n 5 200; for D591/2b3a cells, n 5 180; for D559/
2b3a cells, n 5 192; for RGD-treated 123 cells, n 5 60). The dif-
ference between 123 cell and D591/2b3a cells is highly significant
(P , 0.00001).
Figure 9. A small fragment of 14-3-3z containing the GPIba-
binding site inhibited GPIb-IX–induced cell spreading. Trunca-
tion mutation of 14-3-3z and mapping of the GPIba-binding site
of 14-3-3z were reported previously (Du et al., 1996; Gu and Du,
1998). A truncation mutant of 14-3-3z (T12) contains the binding
site for GPIba (residues 181–231; Gu and Du, 1998). Vectors en-
coding GFP, GFP-14-3-3z fusion protein (1433), and GFP-T12
fusion protein were transiently transfected into 123 cells (stably
expressing integrin aIIbb3 and GPIb-IX) using lipofectamine. Af-
ter 48 h, cells were detached and then allowed to adhere and
spread on botrocetin-treated vWF-coated glass slides. Cells were
then fixed and stained with an antibody against integrin aIIbb3
(D57) followed by rhodamine-labeled goat anti–mouse IgG.
Cells expressing GFP-T12, GFP-14-3-3z, or GFP are shown by
emission of green fluorescence. Shown in the pictures are typical
results from three experiments. To quantitate cell spreading,
green fluorescent cells were counted under the fluorescence mi-
croscope, percentages of round and spread cells from three ex-
periments are shown in the table (mean 6 SD).The Journal of Cell Biology, Volume 147, 1999 1094
vances in understanding the molecular mechanisms of in-
tracellular signaling are often achieved with the use of
recombinant DNA transfection techniques to express spe-
cific intracellular signaling molecules or to specifically al-
ter the function of such a molecule. As platelets do not
have nuclei and cannot be maintained in culture, it is diffi-
cult to use recombinant DNA approach directly. Thus, we
have developed a model system in a CHO cell line ex-
pressing both the human integrin aIIbb3 and GPIb-IX. In
our CHO cell expression model, GPIb-IX mediates signal-
ing leading to the activation of integrin aIIbb3 in a manner
similar to that observed in platelets: (a) vWF binding to
GPIb-IX in our CHO cell model not only induces integrin-
vWF interaction but also induces soluble fibrinogen bind-
ing to the integrin aIIbb3, suggesting that GPIb-IX is un-
likely to be simply presenting aIIbb3 to vWF or inducing
changes in vWF, but is inducing a cellular signal that acti-
vates the ligand-binding function of the integrin (Fig. 3).
This is consistent with previous findings in platelets show-
ing vWF binding to GPIb-IX initiates signaling leading
to integrin aIIbb3 activation (De Marco et al., 1985a,b;
Gralnick et al., 1985; Kroll et al., 1991; Savage et al.,
1992, 1996). (b) We show that GPIb-IX–induced integrin-
dependent cell spreading on vWF was inhibited by pros-
taglandin E1 (PGE1), and the protein kinase C inhibitor
calphostin C (Fig. 2). These inhibitors also inhibit vWF-
induced integrin activation in platelets (Coller, 1981; De
Marco et al., 1985a; Savage et al., 1992; Kroll et al., 1993;
Kroll et al., 1991, 1993). Reconstitution of the platelet
GPIb-IX–mediated activation of aIIbb3 in CHO cells is
thus significant to further understanding the GPIb-IX–
mediated signaling using specific molecular biological ap-
proaches.
In our CHO cell expression model, the vWF modulator,
ristocetin, was used to induce binding of soluble vWF to
GPIb-IX expressed in CHO cells. It is known that plate-
lets do not bind to soluble vWF under physiological con-
ditions. At the site of vascular injury, vWF binds to ex-
posed subendothelial matrix proteins such as collagen.
Collagen binding causes the exposure of the GPIb-IX–
binding site in vWF probably by inducing a conforma-
tional change (Mazzucato et al., 1999). Shear stress may
play a role in the conformational change of vWF induced
by the subendothelial matrix (Siediecki et al., 1996). In
vitro, the effect of subendothelial matrix proteins on vWF
can be mimicked by desialation of vWF (De Marco et al.,
1985a), natural occurring mutations in vWF (De Marco et
al., 1985b; Gralnick et al., 1985) or binding of artificial
vWF modulators such as botrocetin (Andrews et al.,
1989) and ristocetin (Berndt et al., 1985; Kroll et al.,
1991). Although there is a report that ristocetin may
flocculate fibrinogen (Scott et al., 1991) and thus may
increase nonspecific binding of fibrinogen, ristocetin-
induced platelet aggregation in platelet-rich plasma is
dependent on vWF binding to GPIb-IX, indicating that
ristocetin cannot directly induce fibrinogen binding to in-
tegrin aIIbb3. Binding of vWF to platelets induced by
ristocetin and other in vitro methods is similar to vWF
binding induced by subendothelial matrix under flow con-
ditions. In both cases vWF binds to essentially the same
ligand-binding pocket on GPIb-IX in the NH2-terminal
region of GPIba, and can be inhibited by the same mono-
clonal antibodies (e.g., AK2) directed against the NH2-
terminal region of GPIb-IX (Berndt et al., 1988; Vicente
et al., 1988, 1990; Fredrickson et al., 1998). Furthermore,
vWF binding to GPIb-IX induced by vWF modulators,
desialation or mutations initiate similar platelet responses
to that observed when platelets adhere to matrix-bound
vWF. These responses include activation of PKC, eleva-
tion of intracellular calcium, release of thromboxane A2,
release of granule contents, and activation of the integrin
aIIbb3 (Kroll et al., 1991; Savage et al., 1992, 1996, 1998).
For these reasons, ristocetin as a modulator of vWF bind-
ing to GPIb-IX has been commonly used in clinical and
research laboratories. Since all available evidence indi-
cates that GPIb-IX signaling is initiated by vWF binding
to the NH2 terminus of GPIba (Ware, 1998), and the ex-
periments are controlled such that the effects of ristocetin
alone can be excluded (Fig. 3), differences in the methods
of induction of vWF binding (desialation, mutation, mod-
ulators, or shear stress) are unlikely to be a significant fac-
tor causing GPIb-IX signaling to diverge into dramati-
cally different pathways. Thus, data obtained using vWF
modulators such as ristocetin are relevant to understand-
ing GPIb-IX signaling during platelet adhesion to the sub-
endothelial matrix in vivo.
We have shown previously that 14-3-3, an intracellular
signaling molecule, bound to the cytoplasmic domain of
GPIb-IX, and that its binding was dependent upon the
COOH-terminal region of GPIba (Du et al., 1996) and the
helix I region of 14-3-3 (Gu and Du, 1998). In this study,
we have investigated the role of 14-3-3 in GPIb-IX signal-
ing in the CHO cell expression model and show that dele-
tion of the 14-3-3–binding site in the COOH terminus of
GPIba inhibits GPIb-IX–mediated aIIbb3 activation. As
deletion of the COOH-terminal domain of GPIba did not
negatively affect vWF binding to GPIb-IX (Fig. 6), it is un-
likely that the inhibition in integrin activation resulted
from a loss of vWF binding function of the mutant GPIb-
IX. Since this GPIb-IX mutant still interacts with filamin
at a nearby site (Cunningham et al., 1996), it is also un-
likely that a gross disturbance of the tertiary structure of
the GPIba cytoplasmic domain or loss of the interaction
with the filamin-membrane skeleton caused the inhibition
in signaling. Consistent with the importance of 14-3-3 in
vWF-induced signaling, the small dominant negative frag-
ment of 14-3-3 that contains the GPIba-binding site (Gu
and Du, 1998) also inhibited GPIb-IX–mediated integrin
activation (Fig. 7). Thus, we conclude that 14-3-3 binding
to GPIb-IX plays an important role in wild-type GPIb-IX–
mediated signaling leading to integrin activation. This is
the first identified early link between GPIb-IX and the in-
tegrin activation pathway.
Filamin binding to the central region of the GPIba cyto-
plasmic domain links GPIb-IX to the membrane skeleton
structure (cross-linked short actin filaments) underlining
the membrane (Fox et al., 1988). The association of GPIb-
IX with this structure is important for platelets to maintain
a discoid shape (Lopez et al., 1998). A membrane skele-
ton-like structure can also be seen in the CHO cells ex-
pressing GPIb-IX complex (Du, X., unpublished data). It
has been shown previously that truncation of GPIba at
residue 559 abolished association of GPIb-IX with the fil-
amin-membrane skeleton. Cells expressing this truncatedGu et al. Integrin Activation by GPIb-IX 1095
mutant GPIb-IX spread on vWF without coexpression of
aIIbb3 (Cunningham et al., 1996), a process that is inhibited
by RGDS peptides (Du, X., unpublished data). Consistent
with this, we found that D559/2b3a cells expressing this
mutant GPIb-IX and integrin aIIbb3 showed an enhanced
spreading on vWF which was poorly inhibited by anti-
aIIbb3 antibodies that blocked ligand-binding sites but was
significantly inhibited by RGDS peptide (Fig. 7), suggest-
ing that an RGDS-dependent endogenous integrin is re-
sponsible. In contrast to the truncation mutant, cells ex-
pressing wild-type GPIb-IX spread poorly on vWF in the
absence of aIIbb3 (Fig. 2). This suggests that the function of
this endogenous CHO cell integrin to mediate cell spread-
ing on vWF is restrained by the membrane skeleton asso-
ciation with GPIb-IX and enhanced by disruption of this
association. When coexpressed with integrin aIIbb3, how-
ever, wild-type GPIb-IX is able to induce cell spreading on
vWF (Fig. 2) and soluble fibrinogen binding to integrin
aIIbb3. Thus, GPIb-IX–mediated activation of aIIbb3 is not
restrained by the association of GPIb-IX with the mem-
brane skeleton. This suggests that the functions of aIIbb3
and the endogenous integrin are regulated by GPIb-IX via
different mechanisms. Indeed, we showed that GPIb-IX–
mediated activation of integrin aIIbb3 involves the binding
of 14-3-3 to the COOH terminus of GPIba. In contrast,
the D559/2b3a cells expressing the mutant GPIb-IX lack-
ing both filamin and 14-3-3–binding sites were defective in
vWF-induced fibrinogen binding (Fig. 5). It remains un-
clear what types of endogenous CHO cell integrin are re-
sponsible for cell spreading on vWF in the absence of
aIIbb3, and what mechanisms are involved in the upregula-
tion of their function when GPIb-IX is dissociated from
the membrane skeleton. CHO cells express an endoge-
nous vitronectin receptor (av complexed with b1 or possi-
bly b5) and a5b1, both of which are inhibited by RGDS
peptides (Chen et al., 1995; Felding-Habermann and
Cheresh, 1993; Zhang et al., 1995). As these CHO cell in-
tegrins are known to interact with immobilized ligands
without prior activation, one possibility is that binding of
vWF to GPIb-IX may change the conformation of vWF or
bring vWF to the vicinity of the endogenous integrin and
thus allow their interaction via a localized signaling mech-
anism. Disruption of GPIb-IX association with the mem-
brane skeleton may allow free lateral movement of GPIb-
IX to the vicinity of these integrins without the restraint by
the membrane skeleton structure, thus enhancing cell
spreading on vWF. In contrast, the function of aIIbb3 to in-
teract with vWF and soluble fibrinogen is known to re-
quire prior activation via intracellular signaling (Phillips et
al., 1991; Savage et al., 1992). Thus, vWF-induced activa-
tion of aIIbb3 is not restrained by the membrane skeleton
structure, but requires a 14-3-3–dependent signaling mech-
anism.
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